PTLA News and Press, Portola Pharmaceuticals Inc. From 08/07/19

The following slide deck was published by Portola Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings Read more ...

Portola Pharmaceuticals (NASDAQ: PTLA ): Q2 GAAP EPS of -$0.97 beats by $0.05 . Revenue of $28.4M (+608.2% Y/Y) beats by $2.98M . Shares +1.3% . Press Release More news on: Portola Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ...

SOUTH SAN FRANCISCO, Calif. , Aug. 7, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ®  (Nasdaq: PTLA) today reported financial results for the three months ended June 30, 2019 , and provided a corporate update. "This is our fifth consecutive quarter of strong reve...

AAOI , AGO , AIG , ALB , AMPH , ANGI , ARNA , ASRT , ATO , AVLR , AZPN , BKNG , BREW , CABO , CAI , CCMP , CDE , CECO , CLI , COLL , CPA , CPRX , CSGS , CTL , CVNA , CWH , DAR , DOX , DVAX , EB , ECPG , ENS , ENV , ET , EVRG , FG , FLO , FNV , FOSL , ...

SOUTH SAN FRANCISCO, Calif. , Aug. 6, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced the Company's first sales of Ondexxya ® (andexanet alfa) in Europe . These sales mark the initiation of commercial access in Europe to Ondexxya &#x...

SOUTH SAN FRANCISCO, Calif. , Aug. 5, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has increased the maximum reimbursement amount for the New Technology Add-on Payment (NTAP) g...

SOUTH SAN FRANCISCO, Calif. , July 17, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2019 , and provide a general business...

Options can be used to play with a volatile stock in a variety of situations. There are ways to make money if you think the stock will be range bound, increase in value, or decrease in value. I think Portola Pharmaceuticals (NASDAQ: PTLA ) is a company that offers a lot of potential in this re...

SOUTH SAN FRANCISCO, Calif. , July 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced new in vitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and rivaroxaban and the ability of ...

SOUTH SAN FRANCISCO, Calif. , June 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with relapsed/refrac...